Horizon Discovery Group’s molecular reference standards integrated into QIAGEN GeneReader NGS System
Deal demonstrates the impact Horizon's Reference Standards are having in supporting the rapidly growing Next Generation Sequencing (NGS) market.
Horizon Discovery Group has announces that QIAGEN NV will be offering an extensive package of quality control data, generated through the application of Horizon’s Reference Standards, with its GeneReader NGS System.
As part of the project, QIAGEN thoroughly validated its platform using Horizon’s Molecular Reference Standards. The very high levels of consistency seen provided QIAGEN with the confidence to use Horizon’s Standards to generate their data set.
By incorporating this data set into the GeneReader NGS System workflows, QIAGEN is able to reinforce the proven accuracy of its NGS platform, facilitating system setup, quality assurance and training for laboratories.
Further, QIAGEN’s GeneRead QIAact Actionable Insights Tumor Panel is the first in a family of multiplex panels for the GeneReader NGS System targeting the most prevalent types of cancer research, including breast, ovarian, colorectal, lung and melanoma. The accuracy, consistency and reliability of this Panel was validated through extensive testing compared with the control data derived from Horizon’s Reference Standards, proving its performance.
Dr Paul Morrill, President, Products Business, Horizon Discovery Group, commented: “The incorporation of Horizon’s widely-used and well-established Reference Standards as a data set into the GeneReader NGS workflow reinforces the critical role that they play in the adoption of NGS workflows by clinical research laboratories.” He continued: “As the GeneReader and its associated panels are adopted, we anticipate that, in addition to their use as the basis of this data set, our Reference Standards will be used to support ongoing quality control in many labs, and we look forward to continuing to collaborate with QIAGEN as work continues to unlock the full potential of both technologies.”
“We created the GeneReader NGS System to provide the world’s first truly complete solution for next-generation sequencing,” said Jonathan Arnold, QIAGEN’s Oncology Franchise Business Leader. “The excellent quality and consistency of Horizon’s Reference Standards has allowed for the generation of a powerful data set. Their integration into the GeneReader NGS System makes quality assurance easier for users – from system set-up and training laboratory staff to supporting the ongoing quality control of NGS workflows.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.